Evaluation of the Antitumor Efficacy of Human Papillomavirus Type 16 E7-Affitoxin in C57BL/6JNifdc Mice Bearing TC-1 Tumors.

Human papillomavirus (HPV) associated cancers pose a significant global health threat, with HPV 16 being the most common causative type. Current treatments often lack specificity and cause severe side effects. In a previous study, we developed an HPV16 E7 targeted therapeutic agent, Z_HPV16E7 affitoxin384, which effectively inhibited tumor growth in immunodeficient nude mice bearing HPV16-positive cervical tumors. In this study, we further evaluated the antitumor efficacy of Z_HPV16E7 affitoxin384 in immunocompetent C57BL/6JNifdc mice bearing TC-1 tumors. Z_HPV16E7 affitoxin384 had demonstrated specific binding to HPV16 E7 in TC-1 cells, significantly inhibiting their proliferation and promoting apoptosis both in vitro and in vivo. In C57BL/6JNifdc mice, Z_HPV16E7 affitoxin384 effectively suppressed TC-1 tumor growth, with a therapeutic effect comparable to that of cisplatin. Acute toxicity tests indicated dose-dependent toxicity, but no significant organ damage or effects on liver/kidney function or blood parameters were observed at tested doses. This study provides robust evidence supporting Z_HPV16E7 affitoxin384 as a promising targeted therapy for HPV16-induced cancers, highlighting its potential for future clinical applications.